BioCentury | Jan 3, 2005
Finance

Ebb & Flow

...CTCE-9908 for non-small cell lung cancer (NSCLC). The deal was underwritten by Canaccord; Jennings Capital; McFarlane Gordon...
BioCentury | Dec 30, 2004
Financial News

Chemokine prices IPO

...giving it a post-money valuation of C$29.3 million ($23.8 million). Underwriters were Canaccord; Jennings Capital; McFarlane Gordon...
Items per page:
1 - 2 of 2
BioCentury | Jan 3, 2005
Finance

Ebb & Flow

...CTCE-9908 for non-small cell lung cancer (NSCLC). The deal was underwritten by Canaccord; Jennings Capital; McFarlane Gordon...
BioCentury | Dec 30, 2004
Financial News

Chemokine prices IPO

...giving it a post-money valuation of C$29.3 million ($23.8 million). Underwriters were Canaccord; Jennings Capital; McFarlane Gordon...
Items per page:
1 - 2 of 2